Study of Acamprosate in Fragile x Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01911455|
Recruitment Status : Recruiting
First Posted : July 30, 2013
Last Update Posted : July 21, 2017
|Condition or disease||Intervention/treatment||Phase|
|Fragile X Syndrome||Drug: acamprosate Drug: Placebo||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||48 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Double-Blind, Placebo-Controlled Proof of Concept Study in Youth With Fragile X Syndrome|
|Study Start Date :||June 2013|
|Estimated Primary Completion Date :||February 2018|
|Estimated Study Completion Date :||February 2018|
U.S. FDA Resources
Active Comparator: acamprosate
The maximum dose of acamprosate to be used in this study is 666 mg three times daily (total 1998 mg/day) for subjects weight ≥ 50 kg and 1332mg for subjects that weigh < 50 kg.
Other Name: Campral
Placebo Comparator: Placebo
Placebo will be prescribed with the same frequency and duration as the acamprosate group.
- Aberrant Behavior Checklist-Social Withdrawal subscale [ Time Frame: Change from baseline to week 10 ]The ABC is the gold standard parent/caregiver reported behavioral outcome measure for use in developmental disability clinical trials.
- Clinical Global Impressions- Improvement (CGI-I) [ Time Frame: week 10 ]The CGI-I global improvement item is a 7-point Likert scale designed to measure symptomatic change at a specific time as compared to baseline. CGI-I is a gold standard global measure of potential change with treatment in placebo-controlled pharmacotherapy trials in developmental disabilities.
- Aberrant Behavior Checklist- Hyperactivity (ABC-H) [ Time Frame: Change from baseline to week 10 ]The ABC is the gold standard parent/caregiver reported behavioral outcome measure for use in developmental disability clinical trials.
- Aberrant Behavior Checklist-Social Avoidance (ABC-SA) [ Time Frame: Change from baseline to week 10 ]The ABC is the gold standard parent/caregiver reported behavioral outcome measure for use in developmental disability clinical trials.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01911455
|Contact: Katie Friedmann, RNemail@example.com|
|United States, Illinois|
|Rush University Medical Center||Recruiting|
|Chicago, Illinois, United States, 60612|
|Contact: Jamie Chin 312-942-0025 firstname.lastname@example.org|
|Principal Investigator: Elizabeth Berry-Kravis, MD|
|United States, Ohio|
|Cincinnati Children's Hospital Medical Center||Recruiting|
|Cincinnati, Ohio, United States, 45229|
|Contact: Katie Friedmann, RN 513-636-0523 email@example.com|
|Principal Investigator: Craig Erickson, MD|
|Principal Investigator:||Craig Erickson, MD||Children's Hospital Medical Center, Cincinnati|
|Principal Investigator:||Elizabeth Berry-Kravis, MD||Rush University Medical Center|